|1.||Kyoi, Takashi: 4 articles (08/2008 - 11/2003)|
|2.||Amagase, Kikuko: 3 articles (12/2014 - 01/2013)|
|3.||Takeuchi, Koji: 3 articles (12/2014 - 01/2013)|
|4.||Ukai, Yojiro: 3 articles (11/2004 - 11/2003)|
|5.||Shiba, H: 2 articles (08/2015 - 02/2012)|
|6.||Kurihara, H: 2 articles (08/2015 - 02/2012)|
|7.||Fujita, T: 2 articles (08/2015 - 02/2012)|
|8.||Miyagawa, T: 2 articles (08/2015 - 02/2012)|
|9.||Ouhara, K: 2 articles (08/2015 - 02/2012)|
|10.||Izuhara, Chitose: 2 articles (12/2014 - 01/2014)|
|1.||Aphthous Stomatitis (Aphthous Ulcer)
12/01/2001 - "[A case of idiopathic relapsing aphthous stomatitis which was effectively treated by irsogladine maleate]."
02/01/1999 - "Irsogladine maleate, which reinforces gap junctional intercellular communication in vitro, was effective for the treatment of transient and relapsing aphthous stomatitis, as well as symptomatic and drug-induced aphthous stomatitis. "
01/01/2008 - "The improvement in gap-junctional intercellular communication by irsogladine may contribute to the treatment of aphthous stomatitis in patients with BD. "
06/01/2013 - "Within 1-2 weeks after development of aphthous stomatitis, 4 mg irsogladine maleate was orally administered daily to all patients and the therapeutic and adverse effects of irsogladine maleate were examined on every week. "
03/01/2010 - "Irsogladine Maleate in the management of recurrent aphthous stomatitis: a pilot study."
01/01/1984 - "Phase I study of 2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine maleate (MN-1695), a new anti-ulcer agent."
06/15/2012 - "The anti-ulcer agent, irsogladine, increases gap junctions in some cell types. "
01/01/2008 - "Increasing the dose of irsogladine may resolve ulcers resistant to low doses of irsogladine."
06/01/2007 - "Irsogladine maleate (IM), an anti-ulcer drug, is reported to improve gastric blood flow via NO-dependent mechanisms. "
05/10/1993 - "We describe a novel inhibitor of angiogenesis, Irsogladine, an anti-ulcer drug. "
|3.||Stomach Ulcer (Gastric Ulcer)
04/01/2010 - "Irsogladine maleate was effective for treating gastric ulcer after H. "
02/01/2004 - "Irsogladine is a commonly used anti-gastric ulcer agent in Japan, and recent in vivo studies have shown it to have anti-angiogenic properties. "
12/01/2013 - "Irsogladine maleate (IM) is a drug invented to treat gastric ulcers; however, several reports have shown that IM also exerts anti-angiogenetic effects in vitro, in vivo and in humans. "
03/01/2011 - "Irsogladine has previously been shown to accelerate the healing of gastric ulcers after H. "
04/01/2010 - "In the subgroup analysis of cases of eradication failure, the gastric ulcer healing rate was significantly higher in the irsogladine maleate group (57.9%) than in the placebo group (26.1%; chi2 test, P = 0.0366). "
08/01/2015 - "Irsogladine maleate (IM) has previously been shown to regulate inflammation and the cell-cell junctional barrier in HGEC. "
08/14/2008 - "The mucosal protective effects afforded by irsogladine maleate on gastric injury induced by indomethacin are mediated by inhibition of mucosal proinflammatory cytokine production and neutrophil infiltration, leading to suppression of mucosal inflammation and subsequent tissue destruction."
06/01/2012 - "Irsogladine maleate ameliorates inflammation and fibrosis in mice with chronic colitis induced by dextran sulfate sodium."
|5.||Oral Ulcer (Mouth Ulcer)
|8.||Histamine (Histamine Dihydrochloride)
|9.||Acetic Acid (Vinegar)
|5.||Drug Therapy (Chemotherapy)